
Profits over people and microplastics in every meal?
Despite this fact, most Americans remain unaware of just how prevalent microplastics are in our lives. New national research that we conducted with our partners at The 5 Gyres Institute paints a troubling picture: while 77% of Americans say they've heard the term 'microplastics,' only 49% actually understand what it means. Even about half of people—51%—know it's often a result of larger plastic breaking down.
The knowledge gap
That knowledge gap is more than an academic concern. It's a public health crisis, especially when you consider that, after the term is defined for survey respondents, 90% of Americans state that they're worried about microplastics in the human body—and they're right to be. Science confirms that these particles have been found in breast milk, placental tissue, lungs, brains, blood, and more. And studies are increasingly linking microplastics to serious health impacts, including cancer, heart disease, hormone disruption, and infertility.
But even when you close that knowledge gap, people who care often feel stuck. Our research shows that 70% of Americans don't know how to reduce their exposure to microplastics and 67% can't name a single company actively working on the problem (we're hoping to change that!). That sense of powerlessness is as dangerous as the plastic itself, because people want better. They just don't know where to turn.
At Grove, we've seen firsthand that Americans are searching for answers and they're looking to us: to companies, brands, and private-sector leaders. They want healthier homes, safer products, and more sustainable choices. They want corporations to lead—not with vague promises, but with bold, measurable action.
This is our collective moment.
A solution
Consumers didn't create the plastic crisis. We, the private sector, did. For decades, our industries have driven plastic adoption in product design, packaging, and sourcing. And we were lied to and manipulated by the petrochemical and plastics industry that shaped this system. Now, we, the private sector in 2025, must dismantle it.
That means going beyond plastic. It means rejecting outdated systems that rely on single-use packaging, microbeads, and petrochemical-based materials. It means investing in compostable and refillable formats, shifting supply chains, being transparent about ingredients and sourcing, and leaning into the circular economy. It means learning and being aware of the impact plastics are having in our bodies and environments. It means supporting legislation, like the newly introduced bipartisan Microplastics Safety Act, which calls on the FDA and HHS to investigate and report on the health impacts of microplastics.
Most importantly, it means refusing to offload responsibility onto consumers and admitting that recycling, long touted as a solution, simply isn't enough. Only 5% of plastic is recycled and the rest ends up in landfills, incinerators, or breaks down into microplastic particles that pollute our air, food, water, and (if not abundantly clear by now) our bodies.
At Grove, we remain unwavering in our commitment to eliminate plastic from the products we make and sell—and to empower others to do the same. But we can't do it alone.
The cost of inaction
Consumers are demanding accountability. Our research shows that 79% of Americans believe microplastics represent a human and environmental emergency; 82% believe companies should be doing more. But only half (54%) believe that businesses are actually stepping up. That gap is where trust and long-term relevance will be won or lost.
The cost of inaction is rising. Not just in terms of public health, but in trust, consumer confidence, and regulatory risk. There will come a time soon when inaction on microplastics will be seen for what it is: negligent at best, and reckless at worst.
Companies that continue to delay action on plastic pollution aren't just making a business decision. They're making a decision that directly impacts human health. Brands that cling to plastic-heavy models are effectively choosing profits over people, and they'll have to live with the consequences.
But brands that choose to lead? They'll be rewarded with consumer loyalty, resilience, and relevance in a world that's rapidly waking up to this crisis. The science is clear. The public is paying attention. The future will not be plastic. And the time for action is now.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Why Is Sotera Health Company (SHC) Stock Soaring Today
What Happened? Shares of healthcare services company Sotera Health (NASDAQ:) jumped 20% in the morning session after the company reported strong second-quarter 2025 results that surpassed analyst expectations and raised its full-year financial outlook. The healthcare sterilization and lab testing provider announced second-quarter adjusted earnings per share of $0.20, beating analyst estimates of $0.17. Revenue for the quarter came in at $294.3 million, a 6.4% year-over-year increase, which also surpassed the consensus estimate of $275.6 million. The company's profitability also improved, with adjusted EBITDA (a measure of operational profitability) of $150.7 million, beating analyst forecasts by 9.8%. Following the strong performance, Sotera Health raised its full-year 2025 guidance, increasing its forecast for adjusted earnings per share by 7.5% to $0.78 at the midpoint. Is now the time to buy Sotera Health Company? Access our full analysis report here, it's free. What Is The Market Telling Us Sotera Health Company's shares are somewhat volatile and have had 10 moves greater than 5% over the last year. But moves this big are rare even for Sotera Health Company and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 18 days ago when the stock gained 3.4% amid broader positive market sentiment ahead of a busy week for corporate earnings. U.S. stock futures indicated a higher open for the markets, setting a positive tone for investors who were anticipating a heavy slate of earnings reports from major companies during the week. Notably, the earnings season got off to a strong start: More than 85% of the S&P 500 stocks that reported earnings exceeded expectations, according to FactSet data. This robust performance fueled positive sentiment, suggesting that corporate profitability remained resilient despite ongoing economic uncertainties. Sotera Health Company is down 1.4% since the beginning of the year, and at $13.43 per share, it is trading 20.6% below its 52-week high of $16.91 from September 2024. Investors who bought $1,000 worth of Sotera Health Company's shares at the IPO in November 2020 would now be looking at an investment worth $534.90. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
18 minutes ago
- Yahoo
Supplement kratom faces safety concerns: "It's ruining people's lives"
There's growing concern about the safety of consuming a supplement known as kratom, derived from the leaves of a tree native to Southeast Asia that has exploded in popularity in recent years. Used in a variety of products — including drinks, pills, powders and brewed tea leaves — kratom is marketed as an energy booster, relaxant and pain reliever. But it's increasingly blamed for addiction, seizures and in some instances deaths. Kratom is currently banned in six states and Washington, D.C., and at least 18 states have some form of regulation. "There's a common misperception that because it's plant-based ... it's safe or non-addictive, but for kratom that's absolutely not true," said Matthew Rossheim, who researches intoxicating substances. He said he thinks kratom products are too accessible and lack proper warnings on their labels. The FDA has warned consumers not to use kratom, citing risks including substance use disorder, seizures and even death, primarily when mixed with other substances like alcohol. Last week, Health and Human Services Secretary Robert F. Kennedy Jr. announced plans for a crackdown on one kratom compound. "It's ruining people's lives" Jasmine Adeoye, 29, tells CBS News she became hooked on a kratom beverage. While quitting alcohol, she says she became addicted to the drink Feel Free Classic, which contains kratom and is manufactured and sold by Botanic Tonics. She said she heard about it on a podcast. "You're advertised this alcohol alternative, so you feel like it's something totally safe and you start to believe there's something wrong with you when you become addicted to this," she said. Feel Free, like other kratom-based products, is readily available at many convenience stores, largely without regulation or oversight. Adeoye is now using social media to warn others. "There's a lot of people who are struggling in silence and really need help, and it's ruining people's lives for sure," she said. The American Kratom Association told CBS News that it advocates for regulations that aim to keep dangerous kratom products off the market. This includes labeling requirements and bans on kratom sales to minors. Kratom-related lawsuits There have been dozens of wrongful death lawsuits across the country related to kratom. In 2023, a class action lawsuit was filed against Botanic Tonics, alleging Feel Free was misleadingly advertised as a safe alcohol alternative. Instead, the suit claimed it was highly addictive and marketed to people struggling with sobriety. Botanic Tonics has since settled the lawsuit. They told CBS News in a statement they "deeply regret any confusion or harm past marketing may have caused" and say they now provide comprehensive information about their products, including intake limits and clear safety warnings. Global stock markets react to Trump's sweeping tariffs in effect now Sean "Diddy" Combs wants to go back to Madison Square Garden in the future, attorney says Why Trump is calling for Intel CEO's immediate resignation Solve the daily Crossword
Yahoo
18 minutes ago
- Yahoo
Vycor Medical Releases Financial Results for the Three and Six Months Ended June 30, 2025
BOCA RATON, FL - August 8, 2025 (NEWMEDIAWIRE) - Vycor Medical, Inc. ("Vycor" or the "Company") (OTCQB-VYCO), today announced financial results for the three and six months ended June 30, 2025. The Company operates through two business units: Vycor Medical, which produces the ViewSite(TM) Brain Access System (VBAS) for neurosurgery; and NovaVision(R), a business in development which offers therapy programs to help patients recover from visual disorders after stroke or brain injury. Company Highlights The Vycor Medical division revenues for the three and six months ended June 30, 2025 increased by 24% and 28%, respectively, most of the increase being from growth in international markets. Operating profit for the three and six months ended June 30, 2025 was $51,146 and $38,340, respectively, and non-GAAP operating profit for the three and six months ended June 30, 2025 was $84,481 and $106,944, respectively, all substantial increases over the 2024 periods. Vycor entered into new distribution agreements for France and Spain during the six months ended June 30, 2025, two important markets targeted for international expansion. Two new clinical papers were published involving the ViewSite Brain Access System (VBAS) during the three months ended June 30, 2025 in addition to the three papers published during the first three months of the year, bringing the total published peer reviewed clinical papers to 48. The two studies published were systematic reviews of tubular retractors in general brain surgery and neuro-oncology surgery, respectively, and highlighted the clinical advantages of VBAS. A new clinical study on NovaVision's NeuroEyeCoach was published, comparing results from using the program at home or in a clinic. The study concluded that both home-based and clinic-based patients showed meaningful improvements with no significant differences in activities of daily living improvements, validating NeuroEyeCoach as an effective tool, whether used clinically or accessed remotely. This is an important study for the company given the significant drive in healthcare systems worldwide to access digital technologies in home settings. Financial Results For the three months ended June 30, 2025, the Company reported revenue of $496,353, an increase of $90,075 (or 22%) over the same period in 2024. The Vycor Medical division (VBAS) generated revenue of $481,788, an increase of $94,539 (or 24%) over the same period in 2024, most of the increase being from growth in international markets. The gross profit margin for 2025 was 83% versus 91% in 2024, with the lower gross margin in 2025 attributable to validation and shipping costs of new production as well as geographical sales mix. The NovaVision division, which remains in development, generated revenues of $14,565 for the three months ended June 30, 2025, versus $19,029 in 2024, and gross margin of 93%, compared to 95% for 2024. For the six months ended June 30, 2025, the Company reported revenue of $932,731, an increase of $189,485 (or 25%) over the same period in 2024. The Vycor Medical division (VBAS) generated revenue of $900,308, an increase of $194,501 (or 28%) over the same period in 2024, most of the increase being from growth in international markets. The gross profit margin for 2025 was 83% versus 90% in 2024, with the lower gross margin in 2025 attributable to validation and shipping costs of new production as well as sales mix. The NovaVision division, which remains in development, generated revenues of $32,423 for the six months ended June 30, 2025, versus $37,439 in 2024, and gross margin of 94%, compared to 93% for 2024. Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Revenue: Vycor Medical $481,788 $387,249 $900,308 $705,807 NovaVision 14,565 19,029 32,423 37,439 $496,353 $406,278 $932,731 $743,246 Gross Profit Vycor Medical $401,783 $352,963 $743,581 $636,039 NovaVision 13,488 18,152 30,224 35,038 $415,271 $371,115 $773,805 $671,077 For the three months ended June 30, 2025 the Company reported non-GAAP Cash Operating Expenses of $330,790 compared to $339,256 in 2024 and non-GAAP Operating Profit of $84,481 compared to $31,859 in 2024. For the six months ended June 30, 2025 the Company reported non-GAAP Cash Operating Expenses of $666,861 compared to $630,766 in 2024 and non-GAAP Operating Profit of $106,944 compared to $40,311 in 2024. Reconciliation of Non-GAAP Information Management uses certain non-GAAP financial measures (including non-GAAP operating expenses and non-GAAP net loss and loss per share), which exclude non-cash depreciation of purchased assets and non-cash stock-based compensation. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures. Three months ended June 30, 2025 On a GAAP basis the Company reported Operating Expenses of $364,125, an operating profit of $51,146, a net income of $23,887 and net income of $0.00 per share. Vycor's GAAP operating costs include non-cash depreciation of purchased assets ($15,021) and non-cash stock compensation charges ($18,314). The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release. On a non-GAAP basis, taking into account these adjustments, operating expenses were $330,790, non-GAAP operating profit was $84,481, and non-GAAP net income was $57,222 or $0.00 per share. Six months ended June 30, 2025 On a GAAP basis the Company reported Operating Expenses of $735,465, an operating profit of $38,340, a net loss of $176,861 and a loss of $0.01 per share. Vycor's GAAP operating costs include non-cash depreciation of purchased assets ($31,975) and non-cash stock compensation charges ($36,629). The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release. On a non-GAAP basis, taking into account these adjustments, operating expenses were $666,861, non-GAAP operating profit was $106,944, and non-GAAP net loss was $108,257 or $0.00 per share. VYCOR MEDICAL, Statements of Comprehensive Loss(unaudited) For the three months ended June 30, For the six months ended June 30, 2025 2024 2025 2024 Revenue $496,353 $406,278 $932,731 $743,246 Cost of Goods Sold 81,082 35,163 158,926 72,169 Gross Profit 415,271 371,115 773,805 671,077 Operating Expenses: Research and development 4,201 2,263 9,963 2,263 Depreciation and amortization 14,881 14,881 29,761 29,761 Selling, general and administrative 345,043 337,793 695,741 632,407 Total Operating Expenses 364,125 354,937 735,465 664,431 Operating income 51,146 16,178 38,340 6,646 Other Income (Expense) Interest expense: Related Party (12,572) (12,841) (25,142) (24,872) Interest expense: Other (12,862) (13,327) (26,001) (26,665) Other income 4,544 Gain (loss) on foreign currency exchange 1 1 2 (149) Total Other Income (Expense) (25,433) (26,167) (51,141) (47,142) Income (Loss) Before Provision for Income Taxes 25,713 (9,989) (12,801) (40,496) Provision for income taxes - - - - Net Income (Loss) from continuing operations 25,713 (9,989) (12,801) (40,496) Loss from discontinued operations, net of tax (1,826) (49) (1,875) (150) Net Income (Loss) 23,887 (10,038) (14,676) (40,646) Preferred stock dividends - - (162,185) (162,185) Net Income (Loss) Available to Common Stockholders $23,887 ($10,038) ($176,861) ($202,831) Other Comprehensive Income (Loss) Foreign Currency Translation Adjustment - - - - Comprehensive Income (Loss) 23,887 (10,038) ($14,676) ($40,646) Income (Loss) Per Share - basic and diluted Income (Loss) from continuing operations $0.00 ($0.00) ($0.01) ($0.01) Loss from discontinued operations ($0.00) ($0.00) ($0.00) ($0.00) Income (Loss) available to common stockholders $0.00 ($0.00) ($0.01) ($0.01) Weighted Average Number of Shares Outstanding Basic 33,372,796 32,628,835 33,372,796 32,628,835 Weighted Average Number of Shares Outstanding Basic 38,667,862 32,628,835 33,372,796 32,628,835 VYCOR MEDICAL, Reconciliation of Operating Loss and Net Loss(unaudited) For the three months ended For the six months ended June 30, June 30, 2025 2024 2025 2024 GAAP Operating Expenses 364,125 354,937 735,465 664,431 Non-cash depreciation of purchased assets (1) (15,021) (15,681) (31,131) (31,301) Non-cash stock-based compensation (2) (18,314) - (36,629) (2,364) Total Non-GAAP Operating Expense Adjustments (33,335) (15,681) (67,760) (33,665) Non-GAAP Cash Operating Expenses $330,790 $339,256 $667,705 $630,766 GAAP Operating Profit (Loss) 51,146 16,178 38,340 6,646 Non-GAAP Operating Expense Adjustments, as above 33,335 15,681 67,760 33,665 Non-GAAP Operating Profit $84,481 $31,859 $106,100 $40,311 GAAP Net Income (Loss) available to common shareholders $23,887 $(10,038) $(176,861) $(202,831) Non-GAAP Operating Expense Adjustments, as above 33,335 15,681 67,760 33,665 Non-GAAP Net Income (Loss) available to common stockholders $57,222 $5,643 $(109,101) $(169,166) Non-GAAP Income (Loss) Per Share basic and diluted $0.00 $0.00 $(0.00) $(0.01) Weighted Average Number of Shares Outstanding Basic 33,372,796 32,628,835 33,372,796 32,628,835 Weighted Average Number of Shares Outstanding Diluted 38,667,862 32,628,835 33,372,796 32,628,835 (1) Non-Cash depreciation of purchased assetsThese are non-cash charges related to assets which can be impacted by the timing and magnitude of acquisitions. We consider our operating results without these charges when evaluating our ongoing costs and performance and therefore exclude such charges when presenting non-GAAP financial measures. (2) Non-Cash Stock-based compensation expense consists of expense relating to stock-based compensation issued to employees, outside directors and non-employees including stock options, restricted common stock, and warrants. Because of varying available valuation methodologies, subjective assumptions and the fact that these amounts vary in size and timing, we believe that the exclusion of stock-based compensation expense allows for a more accurate comparison of our financial results to previous periods. In addition, we believe it is useful to investors to understand the specific impact of stock-based compensation expenses on our operating results. About Vycor Medical, Inc. With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a publicly traded company (OTCQB: VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared or registered medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Vycor Medical's FDA-cleared ViewSite(TM) Brain Access System (VBAS) a minimally invasive neurosurgical device designed to improve access to brain lesions while reducing tissue damage and enhancing patient outcomes. The VBAS system has been approved and used in over 300 hospitals in the US and in numerous countries internationally. VBAS is protected by 46 issued and 11 pending patents and has been validated through over 45 peer-reviewed studies. These studies demonstrate that use of VBAS results in: less brain tissue damage; less invasive procedure; improved access and better visibility; and reduced operating and recovery time. For an overview of Vycor Medical's VBAS see VBAS Video. NovaVision provides a suite of clinically supported vision rehabilitation therapies aimed at helping patients recover from visual impairments caused by stroke or other brain injury. The Visual Restoration Therapy (VRT) is the only commercialized FDA-cleared therapy for vision rehabilitation following neurological brain damage, making it a unique and important option for patients seeking to regain lost visual capabilities. The complementary NeuroEyeCoach program, clinically supported by a 296-patient study (the largest to date in the neuro visual space), enables dramatic improvements in patients' ability to detect objects in the visual field by training them to make better eye movements with improvement in over 80% of patients. The NovaVision therapies, while showing a positive impact on these patients' lives, still require significant development to allow them to successfully address their market potential. For an overview of NovaVision see NovaVision Video. For the latest information on the company, including media and other coverage, and to learn more, please go online at or in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law. Investor Relations Contacts: B2i Digital:David ShapiroChief Executive OfficerB2i Digital, Officedavid@ Vycor Medical, Inc. Contacts: 951 Broken Sound Parkway, Suite 320Boca Raton, FL. 33487(561) 558-2020info@ LinkedIn: